Issue Date: August 28, 2017
J&J deepens TB drug commitment
Johnson & Johnson has teamed with India’s Institute of Microbial Technology (IMTECH) to develop new treatments for tuberculosis. The goal is safer, more effective, all-oral treatments for multi-drug-resistant TB, as well as TB drugs with novel mechanisms for all people with TB. Scientists from J&J and IMTECH will work together to tackle TB, which in 2015 killed nearly 500,000 people in India. In late 2012, J&J received approval for Sirturo, the first new TB treatment in 40 years.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society